307 related articles for article (PubMed ID: 23777769)
1. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.
Tan D; Horning SJ; Hoppe RT; Levy R; Rosenberg SA; Sigal BM; Warnke RA; Natkunam Y; Han SS; Yuen A; Plevritis SK; Advani RH
Blood; 2013 Aug; 122(6):981-7. PubMed ID: 23777769
[TBL] [Abstract][Full Text] [Related]
2. Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
Hirayama Y; Ishitani K; Ota S; Kurosawa M; Kondo T; Takimoto R; Mori A; Sakai H; Torimoto Y; Yamamoto S; Sato K; Iwasaki H; Kohda K; Ishida T; Kakinoki Y; Fukuhara T; Kato J
Int J Hematol; 2014 Sep; 100(3):281-9. PubMed ID: 25052874
[TBL] [Abstract][Full Text] [Related]
3. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-containing regimens for treatment of follicular lymphoma in adults.
Itchaki G; Gafter-Gvili A; Lahav M; Vidal L; Raanani P; Shpilberg O; Paul M
Cochrane Database Syst Rev; 2013 Jul; (7):CD008909. PubMed ID: 23832787
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
7. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
8. Patterns of survival of follicular lymphomas at a single institution through three decades.
Conconi A; Motta M; Bertoni F; Piona C; Stathis A; Wannesson L; Gracia E; Filho VB; Abreu DR; Mian M; Froesch P; Mazzucchelli L; Ghielmini M; Cavalli F; Zucca E
Leuk Lymphoma; 2010 Jun; 51(6):1028-34. PubMed ID: 20536347
[TBL] [Abstract][Full Text] [Related]
9. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.
Junlén HR; Peterson S; Kimby E; Lockmer S; Lindén O; Nilsson-Ehle H; Erlanson M; Hagberg H; Rådlund A; Hagberg O; Wahlin BE
Leukemia; 2015 Mar; 29(3):668-76. PubMed ID: 25151959
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e172-e183. PubMed ID: 30691994
[TBL] [Abstract][Full Text] [Related]
11. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
12. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
Link BK; Maurer MJ; Nowakowski GS; Ansell SM; Macon WR; Syrbu SI; Slager SL; Thompson CA; Inwards DJ; Johnston PB; Colgan JP; Witzig TE; Habermann TM; Cerhan JR
J Clin Oncol; 2013 Sep; 31(26):3272-8. PubMed ID: 23897955
[TBL] [Abstract][Full Text] [Related]
13. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
15. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
17. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
[TBL] [Abstract][Full Text] [Related]
18. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.
Keegan TH; Moy LM; Foran JM; Alizadeh AA; Chang ET; Shema SJ; Schupp CW; Clarke CA; Glaser SL
Leuk Lymphoma; 2013 Apr; 54(4):743-51. PubMed ID: 22957852
[TBL] [Abstract][Full Text] [Related]
19. Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
Helbig G; Krawczyk-Kulis M; Kopinska A; Liwoch R; Kyrcz-Krzemien S
Med Oncol; 2014 Dec; 31(12):310. PubMed ID: 25373321
[TBL] [Abstract][Full Text] [Related]
20. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
